MedTrace Logo

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

NCT07063212 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-19

No results posted yet for this study

Summary

The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).

Conditions

  • Squamous Cell Carcinoma of Head and Neck
  • Sinus Cancer
  • Nasal Cavity Cancer
  • Oral Cavity Cancer
  • Oropharynx Cancer
  • Hypopharynx Cancer
  • Larynx Cancer
  • Oral Squamous Cell Carcinoma
  • Oropharynx Squamous Cell Carcinoma
  • Hypopharynx Squamous Cell Carcinoma
  • Larynx Squamous Cell Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG

Sacituzumab Govitecan

Sacituzumab govitecan (SG; Trodelvy®) is a trophoblast cell-surface antigen 2 (Trop-2)- directed antibody-drug conjugate

DRUG

Cetuximab

Cetuximab (also known as ERBITUX®) is an epidermal growth factor receptor (EGFR) antagonist

Sponsors & Collaborators

Principal Investigators

  • Winston Wong, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-02
Primary Completion
2028-01-02
Completion
2028-01-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07063212 on ClinicalTrials.gov